ATX-101 Abdominoplasty

Phase 1, Open-label Study of the Safety, Tolerability, and Histological Effect of Single Doses of ATX-101 (Sodium Deoxycholate for Injection) Administered in Abdominal Fat in Subjects Undergoing Abdominoplasty

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00835952

Acronym

ATX-101-08-10

Enrollment

Registered

2009-02-04

Start date

2008-11-30

Completion date

2009-04-30

Last updated

2010-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Characteristics of Subcutaneous Fat

Brief summary

Histopathological study of abdominal fat excised from subjects undergoing abdominoplasty

Interventions

DRUGATX-101

ATX-101 single doses

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

25 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy subjects undergoing planned abdominoplasty

Exclusion criteria

* History of interventions in the abdominal area

Design outcomes

Primary

Measure	Time frame
Adverse events, laboratory test results, physical examinations	1 - 28 days

Secondary

Measure	Time frame
Histopathology	1 - 28 Days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026